Strategic Partnerships Leverage Singulex collaborations with Qiagen, Grifols, and academic institutions to identify co-development or enablement opportunities for companion diagnostics, contract research, and licensed assays in hospital networks and reference labs.

Clinical Commercialization Target expansion of the Clarity platform into new infectious and inflammatory disease tests, focusing on post-market adoption in Europe where CE-marked assays are already available, and pursue U.S. FDA clearance opportunities to broaden market access.

High-Sensitivity Demand Position Single Molecule Counting as a differentiator for ultra-low biomarker detection in oncology, autoimmune, and rare disease monitoring to secure conversations with high-value pharma and translational research customers seeking improved biomarker reliability.

Care Pathway Enablement Explore point-of-care and decentralized testing avenues to complement the Clarity system, targeting clinics and specialty centers that require rapid, precise results to accelerate clinical decisions and patient management.

Geographic Growth Capitalize on existing international presence and regulatory markings to pursue market entry or expansion in EU and other regions, aligning with distributor partnerships and lab networks to scale adoption and recurring revenue.